Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

This trial is testing a combination of two treatments — tislelizumab (an immunotherapy drug that helps the immune system fight cancer) and nab-paclitaxel (a chemotherapy drug) — as a first-line treatment for a specific type of breast cancer called triple-negative breast cancer (TNBC) that has spread to the bones. It is a single-arm study, meaning all participants receive the same treatment. **You may be eligible if...** - You are a woman aged 18–70 with triple-negative breast cancer confirmed by tissue testing (negative for HER2, estrogen, and progesterone receptors) - Your cancer has spread to at least one bone and you have at least one measurable tumor on imaging - You have not had chemotherapy for metastatic disease before (this is your first-line treatment) - You are reasonably functional day-to-day (ECOG 0–1) and expected to survive at least 3 months **You may NOT be eligible if...** - You have had prior chemotherapy for metastatic/advanced disease - You have active autoimmune disease or a condition requiring systemic steroids - You are pregnant or breastfeeding - Your organ function (heart, liver, kidney) does not meet minimum safety levels Talk to your doctor to see if this trial is right for you.